Company Overview

Haleon plc is a global consumer health company focused on developing, manufacturing, and marketing over-the-counter (OTC) healthcare products. The company operates within the consumer healthcare and wellness industry, with a portfolio spanning oral health, pain relief, respiratory health, digestive health, and nutritional supplements. Haleon’s business is primarily driven by established consumer brands that address everyday health needs and are typically non-prescription.

The company’s primary revenue drivers include flagship brands such as Sensodyne, Panadol, Voltaren, Centrum, Theraflu, and Advil, which collectively hold leading market positions in multiple categories. Haleon serves mass retail, pharmacy, healthcare professional, and e-commerce channels, targeting consumers seeking self-care and preventative health solutions. Its strategic advantage lies in its scale, brand recognition, and focus on science-led innovation in consumer health. Haleon was formed in 2022 through the demerger of GSK’s Consumer Healthcare business, which had previously operated as a joint venture between GlaxoSmithKline and Pfizer, marking its transition into an independent publicly listed company.

Business Operations

Haleon operates through a single integrated consumer healthcare business model, with revenue generated across several key product categories, including Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). These categories encompass both everyday-use products and condition-specific solutions, sold primarily through retail pharmacies, supermarkets, and digital platforms. The company maintains vertically integrated capabilities across research and development, manufacturing, and global distribution.

Operationally, Haleon manages a global manufacturing and supply chain network, supported by proprietary formulations, clinical research capabilities, and strong regulatory expertise. The company owns and operates multiple subsidiaries worldwide, including Haleon UK Services Limited and Haleon US Holdings LLC, which support regional commercial and operational activities. Haleon also maintains long-term commercial agreements with GSK plc, particularly in relation to transitional services and certain brand rights, reflecting its historical separation.

Strategic Position & Investments

Haleon’s strategic direction centers on driving sustainable growth through brand investment, geographic expansion, and innovation in science-backed consumer health solutions. The company prioritizes increasing penetration in faster-growing categories such as oral health and VMS, while also expanding its presence in emerging markets. Investment in advertising, digital engagement, and healthcare professional endorsement is a core element of its brand-led growth strategy.

Since its demerger, Haleon has focused more on portfolio optimization and debt reduction than large-scale acquisitions. Notable strategic actions include the divestment of non-core brands and manufacturing assets in select markets to streamline operations. The company continues to invest in emerging areas such as preventative healthcare, gut health, and data-driven consumer insights, while leveraging clinical research to differentiate products in competitive OTC markets.

Geographic Footprint

Haleon operates in more than 100 countries, with major commercial presence across Europe, North America, Asia-Pacific, Latin America, and Africa and the Middle East. Its headquarters are located in London, United Kingdom, which serves as the center for corporate governance and strategic decision-making. The company derives a significant portion of its revenue from developed markets, particularly the United States and Western Europe, while faster growth is driven by China, India, and other emerging economies.

The company maintains manufacturing, research, and distribution facilities across multiple continents, enabling localized production and market responsiveness. Haleon’s international footprint supports broad regulatory coverage and reduces reliance on any single geographic market, positioning it to benefit from global trends toward self-care and aging populations.

Leadership & Governance

Haleon is led by an executive team with extensive experience in consumer goods and healthcare, emphasizing disciplined capital allocation, science-led brand building, and operational excellence. The leadership philosophy centers on responsible self-care, long-term value creation, and maintaining high standards of governance as an independent public company.

Key executives include:

• Brian McNamara – Chief Executive Officer
• Dawn Allen – Chief Financial Officer
• Tara Gilbert – Chief Growth Officer
• Michael Del Pozzo – President, North America
• Katie Jacobson – Chief Legal Officer and Company Secretary

The board and executive management oversee strategic execution, risk management, and compliance, with governance practices aligned to UK public company standards and ongoing obligations under SEC filings and UK regulatory frameworks.